GlassScriptPhysician profile
Ashley Marie Schohn
NPI 1851709323
$15,576.04
in general payments reported to CMS, 2019-2025
73 companies · $5,045 in 2025
The $5,045 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $1,301 · 2023: $3,618 · 2024: $5,045 · 2025: $5,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $993 · Consulting Fee: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,140.36 |
| Education | $992.99 |
| Consulting Fee | $575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,226.87 | 2022-2025 | Alecensa, Polivy, Gavreto |
| Astrazeneca Pharmaceuticals LP | $1,072.11 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Astellas Pharma US INC | $801.83 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Merck Sharp & Dohme LLC | $716.93 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $714.44 | 2022-2025 | |
| Pfizer INC. | $713.60 | 2021-2025 | |
| Janssen Biotech, INC. | $646.61 | 2022-2025 | Tecvayli, Darzalex, Erleada |
| Seagen INC. | $619.66 | 2022-2023 | Padcev, Tukysa |
| Daiichi Sankyo INC. | $529.00 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Celgene Corporation | $516.23 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $515.53 | 2021-2025 | |
| Genzyme Corporation | $483.06 | 2022-2025 | |
| Incyte Corporation | $443.96 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $379.09 | 2021-2025 | |
| Tersera Therapeutics LLC | $363.21 | 2023-2025 | Zoladex |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $341.33 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $330.94 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $324.58 | 2023-2025 | Opdivo, Opdualag, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $313.40 | 2021-2025 | Fruzaqla, Iclusig, Alunbrig |
| Emd Serono, INC. | $294.53 | 2022-2025 | Bavencio, Tepmetko |
| Sumitomo Pharma America, INC. | $275.34 | 2024-2025 | Orgovyx |
| Blueprint Medicines Corporation | $257.75 | 2023-2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $229.79 | 2022-2025 | Ultomiris |
| Genmab U.S., INC. | $221.90 | 2023-2025 | Tivdak, Epkinly |
| Gilead Sciences, INC. | $215.54 | 2023-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $182.98 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbott Laboratories | $173.56 | 2021-2025 | Octrode, Proclaim |
| Sanofi-Aventis U.S. LLC | $169.98 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $152.25 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $143.03 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Regeneron Healthcare Solutions, INC. | $133.89 | 2024-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $119.41 | 2024-2025 | Cabometyx |
| Kite Pharma, INC. | $116.26 | 2024-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $108.68 | 2024 | |
| Coherus Oncology, INC. | $103.44 | 2024-2025 | Loqtorzi |
| Janssen Scientific Affairs, LLC | $102.21 | 2024 | Erleada, Akeega |
| Stemline Therapeutics INC. | $87.77 | 2023-2024 | Orserdu |
| Novo Nordisk INC | $86.81 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $86.31 | 2023-2025 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $80.22 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Beone Medicines USA, INC. | $77.72 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $67.32 | 2023-2024 | Brukinsa |
| Adaptive Biotechnologies Corporation | $65.84 | 2022-2024 | Clonoseq |
| Progenics Pharmaceuticals, INC. | $62.95 | 2023-2024 | Pylarify |
| Adc Therapeutics America, INC. | $62.78 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.42 | 2022-2025 | |
| Springworks Therapeutics, INC. | $53.96 | 2024 | Ogsiveo |
| Karyopharm Therapeutics INC. | $53.79 | 2024-2025 | Xpovio |
| Mirati Therapeutics, INC. | $53.40 | 2023-2024 | Krazati |
| Cti Biopharma Corp. | $50.66 | 2022-2023 | Vonjo |
| Pharmaessentia USA Corporation | $41.07 | 2024-2025 | Besremi |
| Teva Pharmaceuticals USA, INC. | $39.00 | 2021 | |
| Caris Mpi, INC. | $38.38 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $32.41 | 2025 | Carvykti |
| Amgen INC. | $31.06 | 2023 | Lumakras, Kyprolis, Blincyto |
| Kyowa Kirin, INC. | $29.72 | 2023 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $28.71 | 2025 | Romvimza, Qinlock |
| Puma Biotechnology, INC. | $28.42 | 2025 | |
| Iovance Biotherapeutics, INC. | $27.95 | 2025 | Amtagvi |
| Recordati_rare_diseases_inc. | $27.27 | 2025 | Sylvant |
| Sanofi Pasteur INC. | $25.00 | 2021 | |
| Boston Scientific Corporation | $24.24 | 2023 | |
| Geron Corporation | $23.59 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $23.37 | 2023 | Imbruvica, Epkinly |
| Sobi, INC | $22.01 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.41 | 2023 | Xarelto |
| Pharmacosmos Therapeutics INC. | $18.96 | 2025 | Monoferric |
| Immunocore Limited | $16.72 | 2025 | Kimmtrak |
| Biohaven Pharmaceuticals, INC. | $16.52 | 2021 | |
| Servier Pharmaceuticals LLC | $16.44 | 2024 | |
| Intuitive Surgical, INC. | $15.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.94 | 2022 | |
| Phadia US INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
Keytruda $694Orgovyx $562Xtandi $486Epkinly $374Imbruvica $363Zoladex $363Enhertu $346Lenvima $344Reblozyl $333Monjuvi $314Erleada $290Ayvakit $258Talzenna $236Padcev $235Sarclisa $233Alecensa $227Gavreto $225Lynparza $219Tecvayli $211Fabhalta $209Ultomiris $204Polivy $202Darzalex $194Opdivo $184Vitrakvi $174Stivarga $174Verzenio $166Kisqali $164Phesgo $160Welireg $153Tecentriq $149Nubeqa $146Tavalisse $143Rezlidhia $143Jaypirca $137Tukysa $136Tivdak $134Imfinzi $134Pomalyst $133Talvey $133Venclexta $131Xofigo $128Wayrilz $122Bavencio $122Rybrevant $120Cabometyx $119Itovebi $117Yescarta $116Pemazyre $115Elrexfio $115Jakafi $114Brukinsa $112Zepzelca $109Enjaymo $108Opdualag $107Carvykti $107Fotivda $106Pluvicto $106Akeega $102Columvi $102Lunsumio $102Ibrance $99.86Injectafer $98.91Libtayo $96.91Jevtana $94.04Perjeta $93.72Rozlytrek $91.02Orserdu $87.77Onivyde $86.31Keytruda Qlex $83.92Lutathera $82.69Loqtorzi $81.39Cablivi $80.69Ojjaara $72.24Zynyz $70.86Fruzaqla $70.48Iclusig $67.73Braftovi $66.84Alunbrig $66.41Pylarify $62.95Trodelvy $62.19Piqray $60.29Vanflyta $58.50Scemblix $58.35Udenyca $58.35Lorbrena $57.14Retevmo $54.50Ogsiveo $53.96Xpovio $53.79Krazati $53.40Mektovi $51.74Promacta $47.09Vyloy $44.11Xospata $42.88Besremi $41.07Clonoseq $39.06Mi Cancer Seek $38.38Lynozyfic $36.98Tevimbra $32.70Tecentriq Hybreza $32.28
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Schohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.